Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology And Forecast 2026-2036 - Targeted Therapies Reshape Treatment Through 2036
The report provides an in-depth assessment of FSGS epidemiology, treatment practices, market dynamics and commercial opportunities across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan.
The FSGS market in the seven major markets was valued at approximately USD 300 million in 2025 and is projected to expand significantly through 2036. Growth will be supported by increasing diagnosed prevalence, wider use of genetic testing, improved patient stratification, rising disease awareness and the introduction of targeted therapies designed to reduce proteinuria and preserve renal function.
FSGS Epidemiology and Patient Burden
Approximately 213,000 diagnosed prevalent cases of FSGS were recorded across the seven major markets in 2025, with case numbers expected to increase through 2036. The United States represented approximately 36% of the diagnosed population and held the largest market share. Among the EU4 and the United Kingdom, the United Kingdom recorded the highest diagnosed prevalence, followed by Germany.
FSGS prevalence was highest among individuals aged 18-64. Primary FSGS accounted for approximately 80% of the diagnosed FSGS population in the United States during 2025. In Japan, males represented an estimated 61% of diagnosed cases, compared with 39% among females.
Disease heterogeneity remains a major clinical and commercial challenge. Outcomes vary by primary, secondary and genetic subtype, as well as steroid responsiveness and the underlying mechanisms of podocyte injury. Steroid-resistant and steroid-dependent populations account for a disproportionate share of progression to end-stage kidney disease and associated healthcare expenditure.
Current FSGS Treatment Landscape
FSGS treatment focuses on reducing proteinuria, slowing progression and preserving kidney function. Historical management has relied on corticosteroids, immunosuppressive agents and renin-angiotensin-aldosterone system blockade. Relapse, glucocorticoid dependence and treatment resistance continue to limit long-term disease control. Although rituximab may support selected relapse-based strategies, evidence in adults remains limited.
The approval of sparsentan, marketed as FILSPARI, marks a transition toward targeted, non-immunosuppressive FSGS treatment. FILSPARI is a dual endothelin and angiotensin receptor antagonist developed by Travere Therapeutics under a worldwide sublicense from Ligand Pharmaceuticals. The Phase III DUPLEX study reported a 46% reduction in proteinuria, supporting its regulatory pathway. FILSPARI has also received orphan drug designation in the United States and Europe.
In April 2026, Travere Therapeutics announced that the US Food and Drug Administration had approved FILSPARI to reduce proteinuria in adult and pediatric patients aged eight years and older with FSGS without nephrotic syndrome. The product is expected to hold a central position in the evolving treatment algorithm, particularly among patients with primary FSGS and clinically significant proteinuria.
FSGS Pipeline and Competitive Landscape
The FSGS pipeline is advancing toward mechanism-based therapies targeting renal inflammation, fibrosis, glomerular hemodynamics and podocyte dysfunction. Proteinuria reduction is increasingly important as an efficacy endpoint across late-stage clinical programs.
DMX-200, also known as QYTOVRA in certain territories, is a CCR2 inhibitor administered with angiotensin II type 1 receptor blockade. Dimerix is evaluating the candidate in the Phase III ACTION 3 trial. DMX-200 has received orphan drug designation from regulators in the United States, Europe and Japan. In April 2026, Dimerix and Amicus Therapeutics entered an exclusive licensing agreement covering US commercialization of DMX-200 across all indications, including FSGS.
Apecotrep, also designated BI-764198, is an oral TRPC6 inhibitor under development by Boehringer Ingelheim as a targeted, non-immunosuppressive treatment for primary FSGS. In January 2026, the company reported that apecotrep reduced proteinuria by 40% in the 20 mg treatment group versus placebo in a 12-week Phase II trial. The candidate is progressing through late-stage clinical development and has received orphan drug designation in Europe and Japan.
Akebia Therapeutics is also evaluating praliciguat in biopsy-confirmed FSGS. The first patient was dosed in a Phase II study in January 2026. Praliciguat is being investigated for its potential effects on renal hemodynamics and fibrosis.
Leading and emerging participants in the FSGS therapeutics market include Travere Therapeutics, Ligand Pharmaceuticals, Dimerix, Amicus Therapeutics, Boehringer Ingelheim, Akebia Therapeutics, Apellis Pharmaceuticals and Novartis Pharmaceuticals.
FSGS Market Drivers and Unmet Needs
- Increasing chronic kidney disease burden associated with diabetes, hypertension, obesity and aging populations Limited availability of disease-modifying and FSGS-specific therapies High relapse, steroid resistance and progression rates Insufficient validated non-invasive biomarkers for early diagnosis and patient stratification Continued reliance on kidney biopsy for definitive diagnosis Growing development of APOL1 inhibitors, endothelin receptor antagonists, biologics, TRPC inhibitors and dual receptor antagonists Rising demand for treatments that sustainably reduce proteinuria and preserve renal function
Market Outlook and Drug Uptake
FSGS drug adoption between 2026 and 2036 is expected to remain selective but increasingly dynamic. Uptake will be influenced by clinical efficacy, safety, treatment sequencing, diagnostic stratification, reimbursement and positioning alongside established standards of care.
FILSPARI is expected to benefit from its differentiated mechanism and targeted regulatory positioning. DMX-200 may gain use as an add-on treatment for persistent proteinuria and inflammatory kidney injury, while apecotrep may support a podocyte-focused treatment strategy. Praliciguat could provide an additional option if clinical studies confirm meaningful renal and anti-fibrotic benefits.
The report evaluates historical and forecast FSGS market size from 2022 to 2036, therapy-level market share, peak patient share, drug uptake, pricing trends and analogue assessments. It also includes epidemiology-based bottom-up forecasting, patient journey analysis, treatment-addressable market estimates and country-level perspectives from more than 15 key opinion leaders and subject-matter experts.
SWOT and conjoint analyses assess emerging therapies by efficacy, safety, administration, market-entry timing, probability of success and addressable patient population. These findings support strategic planning across clinical development, market access, commercialization, portfolio prioritization and competitive positioning.
Overall, the FSGS market is moving away from broad immunosuppression toward targeted therapies addressing podocyte injury, inflammation, fibrosis and glomerular hemodynamics. Continued pipeline progress, greater diagnostic precision and the adoption of disease-specific treatments are expected to create substantial opportunities across the seven major markets through 2036.
Key Topics Covered
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalyst
4.2. Key Conferences And Meetings
4.3. Key Transactions And Collaborations
4.4. News Flow
5. Epidemiology and Market Methodology of Focal Segmental Glomerulosclerosis (FSGS)
6. Focal Segmental Glomerulosclerosis (FSGS) Market Overview at a Glance
6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2. Market Share of Focal Segmental Glomerulosclerosis (FSGS) by Therapies (%) in the 7MM in 2025
6.3. Market Share of Focal Segmental Glomerulosclerosis (FSGS) by Therapies (%) in the 7MM in 2036
7. Disease Background And Overview of Focal Segmental Glomerulosclerosis (FSGS)
7.1. Introduction
7.2. Causes
7.3. Signs And Symptoms
7.4. Diagnosis
7.4.1. Differential Diagnosis
7.4.2. Diagnostic Algorithm
7.4.3. Diagnostic Guidelines
7.5. Treatment and Management
7.5.1. Treatment Algorithm
7.5.2. Treatment Guidelines
8. Epidemiology and Patient Population of Focal Segmental Glomerulosclerosis (FSGS)
8.1. Key Findings
8.2. Assumption and Rationale
8.3. Total Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the 7MM
8.4. The United States
8.4.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
8.4.2. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
8.4.3. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
8.4.4. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
8.5. EU4 and the UK
8.5.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
8.5.4. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
8.5.5. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
8.5.6. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
8.6. Japan
8.6.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
8.6.2. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
8.6.5. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
8.6.6. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
9. Patient Journey of Focal Segmental Glomerulosclerosis (FSGS)
10. Marketed Therapies
10.1. Marketed Competitive Landscape of Focal Segmental Glomerulosclerosis (FSGS)
10.2. Sparsentan (FILSPARI): Travere Therapeutics and Ligand Pharmaceuticals
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Summary of Pivotal Trials
10.2.5. Analyst Views
11. Emerging Therapies
11.1. Emerging Competitive Landscape of Focal Segmental Glomerulosclerosis (FSGS)
11.2. DMX-200: Dimerix
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.3.1. Clinical Trial Information
11.2.4. Safety and Efficacy
11.2.5. Analyst Views
11.3. BI 764198 (apecotrep): Boehringer Ingelheim
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.3.1. Clinical Trial Information
11.3.4. Safety and Efficacy
11.3.5. Analyst Views
12. Focal Segmental Glomerulosclerosis (FSGS): Seven Major Market Analysis
12.1. Key Findings
12.2. Market Outlook of Focal Segmental Glomerulosclerosis (FSGS)
12.3. Conjoint Analysis of Focal Segmental Glomerulosclerosis (FSGS)
12.4. Key Market Forecast Assumptions
12.4.1. Cost Assumptions
12.4.2. Pricing Trends
12.4.3. Analogue Assessment
12.4.4. Launch Year and Therapy Uptakes
12.5. Total Market Size of Focal Segmental Glomerulosclerosis (FSGS) in the 7MM
12.6. The United States
12.6.1. Total Market Size of Focal Segmental Glomerulosclerosis (FSGS) in the United States
12.6.2. Market Size of Focal Segmental Glomerulosclerosis (FSGS) by Therapies in the United States
12.7. EU4 and the UK
12.7.1. Total Market Size of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
12.7.2. Market Size of Focal Segmental Glomerulosclerosis (FSGS) by Therapies in EU4 and the UK
12.8. Japan
12.8.1. Total Market Size of Focal Segmental Glomerulosclerosis (FSGS) in Japan
12.8.2. Market Size of Focal Segmental Glomerulosclerosis (FSGS) by Therapies in Japan
13. Unmet Needs of Focal Segmental Glomerulosclerosis (FSGS)
14. SWOT Analysis of Focal Segmental Glomerulosclerosis (FSGS)
15. KOL Views of Focal Segmental Glomerulosclerosis (FSGS)
15.1. Expert/KOL Interview Highlights
16. Market FSGSess and Reimbursement of Focal Segmental Glomerulosclerosis (FSGS)
16.1. The US
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. Japan
16.4. Summary and Comparison of Market FSGSess and Pricing Policy Developments in 2025
16.5. Market FSGSess and Reimbursement of Focal Segmental Glomerulosclerosis (FSGS) Therapies
17. Appendix
17.1. Bibliography
17.2. Report Methodology
A selection of companies mentioned in this report includes, but is not limited to:
- Travere Therapeutics Ligand Pharmaceuticals Dimerix Amicus Therapeutics Boehringer Ingelheim Akebia Therapeutics Apellis Pharmaceuticals Novartis Pharmaceuticals
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment